Drug Trial Radar · NCT06116253
Advanced Diffusion Imaging in Renal Cancer Patients
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
39
Actual
Start
Dec 1, 2022
Primary completion
Dec 1, 2028
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- First posted
- Nov 3, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.
Conditions
- Renal Cancer
Interventions
Magnetic Resonance Imaging (MRI) ScanDevice
Participants will undergo a 1-hour research MRI scan.
Tc-99m PentetateDrug
Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Times Lesion Type is Correctly Predicted using IVIM-MRI at Pre-SurgeryTime frame: Baseline (1 Week Prior to Operation)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.